Product Name :
BMS 433796
Description:
BMS 433796 is a γ-secretase inhibitor with Aβ lowering activity in a transgenic mouse model of Alzheimer’s disease.
CAS:
935525-13-6
Molecular Weight:
402.35
Formula:
C19H16F2N4O4
Chemical Name:
1-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-3-[(5S)-3-methyl-4-oxo-4,5-dihydro-3H-2,3-benzodiazepin-5-yl]urea
Smiles :
CN1N=CC2C=CC=CC=2[C@H](NC(=O)NC(=O)[C@@H](O)C2C=C(F)C=C(F)C=2)C1=O
InChiKey:
RDSOIKZEEGAJGL-HOTGVXAUSA-N
InChi :
InChI=1S/C19H16F2N4O4/c1-25-18(28)15(14-5-3-2-4-10(14)9-22-25)23-19(29)24-17(27)16(26)11-6-12(20)8-13(21)7-11/h2-9,15-16,26H,1H3,(H2,23,24,27,29)/t15-,16-/m0/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{Isatuximab} MedChemExpress|{Isatuximab} Apoptosis|{Isatuximab} Technical Information|{Isatuximab} In Vivo|{Isatuximab} custom synthesis|{Isatuximab} Epigenetic Reader Domain}
Shelf Life:
≥12 months if stored properly.{{Pralsetinib} web|{Pralsetinib} Protein Tyrosine Kinase/RTK|{Pralsetinib} Purity & Documentation|{Pralsetinib} References|{Pralsetinib} supplier|{Pralsetinib} Cancer}
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
BMS 433796 is a γ-secretase inhibitor with Aβ lowering activity in a transgenic mouse model of Alzheimer’s disease.|Product information|CAS Number: 935525-13-6|Molecular Weight: 402.35|Formula: C19H16F2N4O4|Chemical Name: 1-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]-3-[(5S)-3-methyl-4-oxo-4,5-dihydro-3H-2,3-benzodiazepin-5-yl]urea|Smiles: CN1N=CC2C=CC=CC=2[C@H](NC(=O)NC(=O)[C@@H](O)C2C=C(F)C=C(F)C=2)C1=O|InChiKey: RDSOIKZEEGAJGL-HOTGVXAUSA-N|InChi: InChI=1S/C19H16F2N4O4/c1-25-18(28)15(14-5-3-2-4-10(14)9-22-25)23-19(29)24-17(27)16(26)11-6-12(20)8-13(21)7-11/h2-9,15-16,26H,1H3,(H2,23,24,27,29)/t15-,16-/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.PMID:24381199 |Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|BMS-433796 cause a concentration-dependent decrease in [3H]IN973 binding, with IC50 value of 1.2 nM, very similar to the IC50 values for inhibition of Aβ40 in human embryonic kidney cells overexpressing the Swedish mutation of APP of 0.8 nM, respectively, and for inhibition of Aβ42 of 0.4 nM, respectively.|In Vivo:|BMS 433796 is characterized in pharmacokinetic studies in male Sprague-Dawley rats. Following a 10-min intravenous infusion at 2.3 μmol/kg in PEG-400, the total body clearance of 40 is 5.2±0.82 mL/min/kg (means±SEM; n=3), indicating low clearance. The apparent terminal elimination half-life is 4.6±0.48 h. Oral administration of a PEG-400 suspension at 35 μmol/kg shows an oral bioavailability of 31% with prolonged absorption. BMS 433796 has satisfactory metabolic stability in human liver microsomal preparations and is not an inhibitor of human CYPs (IC50>100 μM). Brain Aβ40 is reduced as a result of administering BMS-433796 in a dose-dependent manner, with ED50 value of 2.4 mg/kg, respectively.|Products are for research use only. Not for human use.|